Navigation Links
Key genetic mutations could be new hope for adrenocortical tumor patients
Date:4/4/2014

April 3, 2014, Shenzhen, China - Chinese researchers from Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, BGI, and other institutions have discovered that the activating hotspot L205R mutation in PRKACA gene was closely associated with adrenocortical tumors (ACTs), and the relationship of recurrently mutated DOT1L and CLASP2 with ACTs' other subtypes. The latest study published online in Science opens a new insight into diagnosis and treatment of Adrenal Cushing's syndrome.

Adrenal Cushing's syndrome results from autonomous production of cortisol (ACTH-independent) from adrenocortical tumors (ACTs), which may lead to a series of metabolic disorders such as obesity, glucose intolerance and hypertension. However, the genetic architecture of Adrenal Cushing's syndrome remains largely uncharacterized, hampering the development of diagnostic and therapeutic approaches for Cushing's syndrome.

In this study, researchers performed whole-exome sequencing of 49 blood-tumor pairs and RNA sequencing of 44 tumors from cortisol-producing adrenocortical adenomas (ACAs), ACTH-independent macronodular adrenocortical hyperplasia (AIMAH), and adrenocortical oncocytoma (ADO). They found there was a hotspot L205R mutation in PRKACA gene, and two novel mutated genes that have never been reported: One is DOT1L, which may contribute the tumorigenesis of AIMAH; the other is HDAC9, which would be responsible for ADOs.

In the large-scale validation stage, researchers found that L205R mutation was only found in the ACTs, and located in the highly conserved functional domain-P+1 loop of PKA catalytic subunit-plays an important role in the combination of kinase and substrate. The further molecular and cell function validation proved that L205R mutation caused the increase of protein activity and enhanced the catalytic capability of the phosphorylation, and promoted the occurrence of tumor and the production of steroid by substrate phos
'/>"/>

Contact: Jia Liu
liujia@genomics.cn
BGI Shenzhen
Source:Eurekalert

Page: 1 2

Related biology news :

1. Examination of a cave-dwelling fish finds a possible genetic link to human disorders
2. Xiangling Wang, M.D., Ph.D. receives Pfizer/ACMG Foundation Clinical Genetics Fellowship
3. Genetic markers may predict when people with heart disease are likely to have a heart attack
4. Erasing a genetic mutation
5. Genetic mutations warn of skin cancer risk
6. Drilling into the trends in genetics and epigenetics of aging and longevity
7. Faster genetic testing method will likely transform care for patients with breast cancer
8. Genetics can explain why infections can trigger rheumatoid arthritis
9. Certain genetic variants may put bladder cancer patients at increased risk of recurrence
10. MRI reveals genetic activity
11. UT Southwestern ob/gyn researchers studying genetic factors in premature births
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/6/2015)... Aug. 6, 2015  Today, U.S. Congressman ... Crossmatch ™ to learn firsthand how Silicon Valley ... Crossmatch is a world leader in multi-factor identity ... are helping federal agencies and commercial organizations achieve ... "The vast majority of network breaches ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors market ... in applications, penetration into newer sectors, and development of ... global biosensors space has seen the entry of multiple ... so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( ...
(Date:7/31/2015)... China , 31 de julio de 2015 /PRNewswire/ ... Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 de ... . La conferencia celebra su décimo aniversario ... ha convertido en una de las reuniones anuales más ... y es una de las conferencias científicas más dinámicas, ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... An organelle called the nucleolus resides deep within the ... critical functions: it manufactures ribosomes, the molecular machines that ... proteins that do the work of life. , ... Sciences Division of the Department of Energy's Lawrence Berkeley ...
... A solar-powered robot with 20/20 vision, on a search-and-destroy quest ... crop rows at the experimental fields at the University of ... weeds while significantly reducing herbicide use. , The robot uses ... on a frame on top of the machine to give ...
... Women infected with dormant toxoplasmosis are more likely to ... negative, according to research by S. Kankova and colleagues ... University; the Centre of Reproductive Medicine; and GynCentrum, in ... of the parasite Toxoplasma gondii in the mothers' blood, ...
Cached Biology News:Regulating the nuclear architecture of the cell 2Regulating the nuclear architecture of the cell 3Regulating the nuclear architecture of the cell 4Regulating the nuclear architecture of the cell 5New system could drastically reduce herbicide use 2New system could drastically reduce herbicide use 3Bad blood between boys and girls 2
(Date:8/31/2015)... , ... August 31, 2015 , ... ... the world's most successful food and beverage processors, equipment manufacturers and leaders in ... product inspection and industrial weighing and formulation for manufacturers of bakery and snacks; ...
(Date:8/28/2015)... According to a new market ... Systems, Thawing Equipment, Alarms), by Biospecimen (Human Tissue, Stem ... User - Global Forecast to 2020", published by MarketsandMarkets, ... 3,731.03 Million by 2020 from USD 2,150.48 Million in ... and 2020. Browse 74 Tables and ...
(Date:8/28/2015)... ... August 28, 2015 , ... Since the initial launch of FireflySci Inc. (FFS) in early 2015, ... customer service. Images such as the Fonz in a lab coat and Large Marge ... the humdrum spectroscopy field. , FireflySci is proud to be the only cuvette ...
(Date:8/27/2015)... 2015 The National Necrotizing Fasciitis Foundation ... saved by doctors at Vanderbilt University Hospital in ... Pharmaceuticals and Dr. John Crew , director of ... Medical Center in Daly City, CA. ... approach, pioneered by Dr. Crew, that had previously saved ...
Breaking Biology Technology:METTLER TOLEDO Hosts Food Safety Educational Center at 2015 PROCESS EXPO 2Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3
... JLL Partners, a leading private equity investment fund ("JLL") ... JLL PharmaNet Holdings, LLC ("Parent"), through its wholly-owned subsidiary, ... affiliate of JLL, has commenced a tender offer for ... ) at a price of $5.00 per share net ...
... Calif., Feb. 12 BioMarin Pharmaceutical,Inc. (Nasdaq: ... first interim efficacy,analysis (IEA) for the Riquent(R) Phase ... determined that the continuation of the trial is,futile. ... decided to stop the,study, unblind the data and ...
... America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord ... on bringing the life saving potential of stem cells ... that between January 1, 2009, and today, it has ... Company previously said in press releases and CEO interviews ...
Cached Biology Technology:An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share 2An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share 3An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share 4An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share 5An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share 6An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share 7Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile 2Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile 3Cord Blood Announces $1 Million Reduction in Long Term Debt 2